Overview

Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With Donepezil

Status:
Completed

Trial end date:
2016-07-01

Target enrollment:

Participant gender:

Summary

To establish efficacy of idalopirdine as adjunctive therapy to donepezil for symptomatic treatment of patients with mild-to-moderate Alzheimer's disease (AD).

Phase:

Phase 3

Details

Lead Sponsor:

H. Lundbeck A/S

Collaborator:

Otsuka Pharmaceutical Co., Ltd.

Treatments:

Donepezil